The findings establish RegoNeo as a promising personalized immunotherapy that reprograms the immunosuppressive tumor microenvironment by increasing Rgs2+CD8+ T cell infiltration, highlighting both the treatment approach and this specific T cell subset as potential therapeutic targets for MSS‐CRLM patients. The gene discussed is RGS2; the disease is neoplasm.